Open Journal Systems

Strategy to achieve biomarker-driven immunosuppression after solid organ transplantation by an academic-industry partnership within the European BIO-DrIM consortium

Hans-Dieter Volk, Bernhard Banas, Frederike Bemelman, Oriol Bestard, Sophie Brouard, Cristina Cuturi, Josep M Grinyó, Maria Hernandez-Fuentes, Martina Koch, Björn Nashan, Irene Rebollo-Mesa, Alberto Sanchez-Fueyo, Birgit Sawitzki, Ineke JM ten Berge, Ondrej Viklicky, Kathryn Wood K, Petra Reinke

Article ID: 5
Vol 1, Issue 1, 2016, Article identifier:12-24

VIEWS - 887 (Abstract) 606 (PDF)


Solid organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure as it improves both quality of life and survival. Despite the progress in short-term graft survival, that is closely associated with the impressive reduction of acute rejections within the first year, long-term graft and patient survival remain almost un-changed and unsatisfactory. Incomplete control of chronic allograft injury but particularly the adverse effects of long-term immunosuppression, such as graft toxicity, diabetes, cardiovascular events, infections, and tumours continue to challenge the long-term success. In general, immunosuppression is applied as one-size-fits-all strategy. This can result in over- and under-immunosuppression of patients with low and high alloresponsiveness, respectively. Trial- and -error strategies to minimize or even completely wean of immunosuppression have a high failure rate. Consequently, there is an unmet medical need to develop biomarkers allowing objective risk stratification of transplant patients. To achieve this goal, we engaged in an academic-industrial partnership. The central focus of the European-wide BIO-DrIM consortium (BIOmarker-Driven IMmmunosuppression) is the implementation of biomarker-guided strategies for personalizing immunosuppression to improve the long-term outcome and to decrease the adverse effects and costs of chronic immunosuppression in solid organ transplant patients. The concept includes four innovative investigator-driven clinical trials designed by the consortium.


BIO-DrIM; personalized immunosuppression; biomarker; solid organ transplantation; stratification into high/low responder patients; Elispot; multiparameter flow cytometry; urinary IP-10; health-economic analyses

Full Text:


Included Database


Casey M J and Meier-Kriesche H U, 2011, Calcineurin inhibitors in kidney transplantation – friend or foe? Current Opinion in Nephrology Hypertens, vol.20(6): 610– 615.

Rostaing L and Karnar, 2010, mTOR inhibitor/prolifera-tion signal inhibitors: entering or leaving the filed? Journal of Nephrology, vol.2: 133–142.

Martínez-Llordella M, Lozano J J, Puig-Pey I, et al. 2009, Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. Journal of Clinical Investigation, vol.118: 2845– 2857.

Sánchez-Fueyo A, 2011, Hot debate on tolerance: immunosuppression withdrawal. Liver Transplantation, vol.17: S69–S73.

Brouard S, Mansfield E, Braud C, et al. 2007, Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proceedings of the National Academy of Sciences of the United States of America, vol.104: 15448–15453.

Pallier A, Hillion S, Danger R, et al. 2010, Patients with drug free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney International, vol.78(5): 503– 513.

Sagoo P, Perucha E, Sawitzki B, et al. 2011, Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. Journal of Clinical Investigation, vol.120: 1848–1861.

Hernandez-Fuentes M P and Lechler R A, 2010, ‘Bio-marker signature’ for tolerance in transplantation. Nature Reviews Nephrology, vol.6: 606–613.

Lozano J J, Pallier A, Martinez-Llordella M, et al. 2011, Comparison of transcriptional and blood cell-phenotypic markers between operationally tolerant liver and kidney recipients. American Journal of Transplantation, vol.11: 1916–1926.

Brouard S, Giral M, Soulillou J P, et al. 2011, Elaboration of gene expression-based clinical decision aids for kidney transplantation: where do we stand? Transplantation, vol.91: 691–69.

Nickel P, Bestard O, Volk H D, et al. 2009, Diagnostic value of T-cell monitoring assays in kidney transplanta-tion. Current Opinion in Organ Transplantation, vol.14: 426–431.

Andree H, Nickel P, Nasiadko C, et al. 2006, Identification of dialysis patients with panel-reactive memory T cells before transplantation using an allogeneic cell bank Journal of the American Society of Nephrology, vol.17: 573–580.

Sawitzki B, Reinke P, Pascher A, et al. 2010, State of the art on the research for biomarkers allowing individual, tailor-made minimization of immunosuppression. Current Opinion in Organ Transplantation, vol.15: 691– 696.

Sawitzki B, Bushell A, Steger U, et al. 2007, Identification of gene markers for the prediction of allograft re-jection or permanent acceptance. American Journal of Transplantation, vol.7: 1091–1102.

Bestard O, Nickel P, Cruzado J M, et al. 2008, Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. Journal of the American Society of Nephrology, vol.19: 1419–1429.

Nadig S N, Wieckiewicz J, Wu D C, et al. 2010, In vivo prevention of transplant arteriosclerosis by ex vivo ex-panded human regulatory T cells. Nature Medicine, vol.16: 809–813.

Hricik D E, Rodriguez V, Riley J, et al. 2013, Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. American Journal of Transplantation, vol.3: 878–884.

Sanchez-Fueyo A, 2013, Tolerance profiles and immunosuppression. Liver Transplantation, vol.19(Suppl 2): S44–S48.

Viklicky O, Krystufkova E, Brabcova I, et al. 2013, B-cell-related biomarkers of tolerance are up-regulated in rejection-free kidney transplant recipients. Trans-plantation, vol.95: 148–154.

Streitz M, Miloud T, Kapinsky M, et al. 2013, Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplantation Research, vol.2: 17–23.

Gerlach U A, Vogt K, Schlickeiser S, et al. 2013, Elevation of CD4+ differentiated memory T cells is associated with acute cellular and antibody-mediated rejection after liver transplantation. Transplantation, vol.95: 1512–1520.

Sawitzki B, Schlickeiser S, Reinke P, et al. 2009, Pre-transplant immune risk assessment. Current Opinion in Organ Transplantation, vol.14: 650–655.

Hu H, Aizenstein B D, Puchalski A, et al. 2004, Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. American Journal of Transplantation, vol.4: 432–437.

Matz M, Beyer J, Wunsch D, et al. 2006, Early post- transplant urinary IP-10 expression after kidney trans-plantation is predictive of short- and long-term graft function. Kidney International, vol.69: 1683–1690.

Dziubianau M, Hecht J, Kuchenbecker L, et al. 2013, TCR repertoire analysis by next generation sequencing allows complex differential diagnosis of T cell-related pathology. American Journal of Transplantation, vol.13: 2842–2854.

Lei H, Kuchenbecker L, Streitz M, et al. 2015, Human CD45RA(low) FoxP3(high) memory-type regulatory T cells show distinct TCR repertoires with conventional T cells and play an important role in controlling early immune activation. American Journal of Transplantation, vol.15: 2625–2635.

Wieczorek G, Asemissen A, Model F, et al. 2009, Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Research, vol.69: 599–608.

Krepsova E, Tycova I, Sekerkova A, et al. 2015, Effect of induction therapy on the expression of molecular markers associated with rejection and tolerance. BMC Nephrology, vol.16: 146–151.

Sawitzki B, Brunstein C, Meisel C, et al. 2014, Prevention of graft-versus-host disease by adoptive T regulatory therapy is associated with active repression of peripheral blood toll-like receptor 5 mRNA expression. Biology of Blood and Marrow Transplantation, vol.20: 173–182.

Hutchinson J A, Riquelme P, Sawitzki B, et al. 2011, Cutting edge: immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. Journal of Immunology, vol.187: 2072–2078.

Keeren K, Friedrich M, Gebuhr I, et al. 2009, Expression of tolerance associated gene-1, a mitochondrial protein inhibiting T cell activation, can be used to predict response to immune modulating therapies. Journal of Immunology, vol.183: 4077–4087.

Benítez C, Londoño M C, Miquel R, et al. 2013, Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology, vol.58: 1824–1835.

Donckier V, Craciun L, Miqueu P, et al. 2013, Expansion of memory-type CD8+ T cells correlates with the failure of early immunosuppression withdrawal after cadaver liver transplantation using high-dose ATG in-duction and rapamycin. Transplantation, vol.96: 306– 315.

Bohne F, Martínez-Llordella M, Lozano J J, et al. 2012, Intra-graft expression of genes involved in iron ho-meostasis predicts the development of operational tolerance in human liver transplantation. Journal of Clin-ical Investigation, vol.122: 368–382.

Bonaccorsi-Riani E, Danger R, Lozano J J, et al. 2015, Iron deficiency impairs intra-hepatic lymphocyte mediated immune response. PLoS One, vol.10: e0136106.

Siepert A, Ahrlich S, Vogt K, et al. 2012, Permanent CNI treatment for prevention of renal allograft rejection in sensitized hosts can be replaced by regulatory T cells. American Journal of Transplantation, vol.12: 2384– 2394.

Bestard O, Cruzado J M, Lucia M, et al. 2013, Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation. Kidney International, vol.84: 1226–1236.

Bestard O, Crespo E, Stein M, et al. 2013, Cross-validation of IFN-γ Elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients. American Journal of Transplantation, vol.13: 1880–1890.

(887 Abstract Views, 606 PDF Downloads)


  • There are currently no refbacks.

Copyright (c) 2016 Hans-Dieter Volk, Bernhard Banas, Frederike Bemelman, Oriol Bestard, Sophie Brouard, Cristina Cuturi, Josep M Grinyó, Maria Hernandez-Fuentes, Martina Koch, Björn Nashan, Irene Rebollo-Mesa, Alberto Sanchez-Fueyo, Birgit Sawitzki, Ineke JM ten Berge, Ondrej Viklicky, Kathryn Wood K, Petra Reinke

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.




Advances in Precision Medicine is a peer-reviewed, open-access journal. All journal content, except where otherwise noted, is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.